Maldonado Dawn, Patel Urja, Tarlin Nancy
Internal Medicine, Mount Sinai Medical Center/Elmhurst Hospital Center, New York City, USA.
Endocrinology, Mount Sinai Medical Center/Elmhurst Hospital Center, New York City, USA.
Cureus. 2020 Aug 14;12(8):e9737. doi: 10.7759/cureus.9737.
We present a case of myxedema coma refractory to traditional treatments. Morbidity and mortality from myxedema coma are frequently due to a missed or delayed diagnosis. It tends to respond very well to intravenous levothyroxine replenishment as long as this treatment is initiated early. We report a case of a 71-year-old man who presented with altered mental status and severe bradycardia who was promptly diagnosed with myxedema coma on laboratory studies sent in the emergency department (thyroid-stimulating hormone 94.74, free T4 0.17, and free T3 0.69). However, while the diagnosis was recognized immediately, and he was treated aggressively with intravenous thyroxine replacement, he strangely remained refractory to treatment for a prolonged period of time. While he did respond to intravenous thyroxine initially, he dramatically decompensated each time he was transitioned to oral therapy. This case brings to question why rarely certain patients fail the transition to oral therapy, and how to treat these patients.
我们报告一例对传统治疗无效的黏液性水肿昏迷病例。黏液性水肿昏迷的发病率和死亡率通常归因于诊断延误或漏诊。只要早期开始治疗,静脉补充左甲状腺素往往疗效显著。我们报告一例71岁男性病例,该患者因精神状态改变和严重心动过缓就诊,急诊科实验室检查(促甲状腺激素94.74、游离T4 0.17、游离T3 0.69)提示黏液性水肿昏迷,诊断明确。然而,尽管诊断迅速明确,且积极给予静脉甲状腺素替代治疗,但奇怪的是,他在很长一段时间内对治疗仍无反应。虽然他最初对静脉甲状腺素有反应,但每次转为口服治疗时病情都会急剧恶化。该病例引发了这样的疑问:为何某些患者很少在转为口服治疗时失败,以及如何治疗这些患者。